Arnberg 1998.

Study characteristics
Methods	Placebo‐controlled, not blinded, industry and public‐sponsored, single‐center trial
Participants	Adults; mixed tumors; ANC < 1 x 109/L
Interventions	GM‐CSF (not specified) 5.5 mcg/kg SC ATB: Many different antibiotics
Outcomes	Overall mortality Bone and joint pain or flu‐like symptoms Deep vein thrombosis
Notes	Hospital discharge criteria: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	We were not able to assess the adequacy of method of sequence generation based on the information provided in the article
Allocation concealment (selection bias)	Unclear risk	We were not able to assess the adequacy of allocation concealment based on the information provided in the article
Blinding (performance bias and detection bias) All outcomes	Low risk	Double blinding was employed
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	We were not able to assess who were blinded based on the information provided in the article
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	We were not able to assess the outcomes for which blinding was employed based on the information provided in the article
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis used, withdrawals are described
Other bias	Unclear risk	Prespecified values of sample size, alpha and beta errors were not provided